St. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care.
St. Claraspital is a leading, systemically relevant hospital in Northwestern Switzerland, delivering high-quality care ranging from primary care services to highly complex treatments, with a particular focus on tumor and abdominal care. A round-the-clock emergency department and intensive care unit, supported by specialized, adjacent and diagnostic disciplines, ensure seamless and integrated patient care.
USB is one of Switzerland’s leading university hospitals and the largest healthcare center in Northwestern Switzerland. Founded in 1460 as part of the University of Basel’s Faculty of Medicine, USB now employs around 8,000 staff members, operates more than 700 beds and treats approximately 40,000 inpatients each year. Comprising 12 medical centers, USB offers comprehensive care across all medical specialties and collaborates closely with the University of Basel and leading life sciences companies.
Oaklins’ team in Switzerland acted as the lead advisor to the seller throughout the sales process, including preparation and approach, due diligence and parallel negotiations with potential buyers.
Raymond Cron
Chairman of the Board, St. Claraspital AG
Talk to the deal team
Related deals
Medicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn moreIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
Learn more